Human Genome Sciences - 500 Beiträge pro Seite

[bernie55]

Analysten-Bewertung - 06.01.06
Human Genome Sciences "buy"


Die Analysten der Citigroup stufen die Aktie von Human Genome Sciences (/ ) unverändert mit "buy" ein und bestätigen das Kursziel von 12 USD. Der vielversprechendste Kandidat der Pipeline sei Albuferon zur Behandlung von Hepatitis C. auf Grund positiver Phase IIb-Daten erwarte man den Abschluss einer lukrativen Partnerschaft und den Beginn einer Phase III-Testreihe Ende 2006. Die Aktie habe die Gunst der Investoren auf Grund negativer Assoziationen im Zusammenhang mit der Genom-Blase und dem kürzlichen Scheitern von LymphoStat-B (rheumatische Arthritis) verloren. Nach Ansicht der Analysten würden Anleger den Wert von Albuferon übersehen, dass eine sehr starke Wettbewerbsposition besitze. Die Aktie gehöre zu den Top-Empfehlungen in 2006. Vor diesem Hintergrund bleiben die Analysten der Citigroup bei ihrer Empfehlung die Aktie von Human Genome Sciences zu kaufen.

Quelle: Citigroup

[bernie55]

aktuell 9,68 USD - + 6,84 %



..und noch eine Analystenempfehlung aus 2005


Analysten-Bewertung - 14.12.05
Human Genome Sciences "outperform"


Die Aktienanalysten von Piper Jaffray bewerten den Anteilsschein des US-amerikanischen Biotechnologieunternehmens Human Genome Sciences (/ ) weiterhin mit "outperform". Am gestrigen Tage habe Human Genome Sciences bekannt gegeben, dass es CoGenesys abspalten werde. Hierbei handele es sich um die Sparte, die Medikamente in der frühen Anfangsphase entwickle. CoGenesys sei im 1. Quartal des laufenden Jahres gegründet worden. Der derzeitige Finanzvorstand von Human Genome Sciences Steve Mayer werde das Unternehmen verlassen und stattdessen als neuer Vorstandsvorsitzender zu CoGenesys wechseln. CoGenesys solle von Human Genome Sciences einen Startup-Kredit in Höhe von 10 Mio. USD erhalten. Dieser Kredit könne entweder mit Kassenbeständen oder mit Wertpapieren zurückgezahlt werden. Human Genome Sciences werde am Umsatz von erfolgreichen Produkten und Partnerschaften von CoGenesys beteiligt werden. Das abgespaltene Unternehmen werde seinen Betrieb mit zunächst 60 Mitarbeitern von Human Genome Sciences aufnehmen. Das Labor werde über eine Größe von 48.000 Quadratmeter verfügen. Nach Ansicht der Analysen von Piper Jaffray sei die Abspaltung positiv zu beurteilen, da sich Human Genome Sciences nun auf die im späteren Entwicklungsstadium befindlichen Medikamente konzentrieren könne. Das bisherige Kursziel von 15 USD werde bestätigt. Die Analysen von Piper Jaffray geben dem Wertpapier von Human Genome Sciences weiterhin das Rating "outperform".

Quelle: Piper Jaffray

[[KERN]Codex]

huhu bernie55

bei hgsi tut sich was!

[bernie55]

Hier die mögliche Verlaufskurve HGSI

- von STOCK100 erstellt am 6.1.06

[bernie55]

Human Genome Sciences kooperiert mit Amgen


Das amerikanische Biotechnologieunternehmen Human Genome Sciences Inc. (ISIN US4449031081/ WKN 889323) verkündete am Montag einen Kooperationsvertrag mit dem weltgrößten Biotechnologiekonzern Amgen Inc. (ISIN US0311621009/ WKN 867900).

Demnach hat Amgen exclusive und weltweite Rechte zur Entwicklung und Kommerzialisierung bestimmter Produkte zur Behandlung von Krebs und nicht-exclusive Rechte zur Entwicklung und Kommerzialisierung bestimmter Diagnoseprodukte, welche auf einem von Human Genome Sciences entdeckten menschlichen Gen basieren, erworben.

Im Gegenzug erhält Human Genome Sciences eine Vorauszahlung, jährliche Lizenzgebühren sowie erfolgsabhängige Meilensteinzahlungen.

Aktien von Human Genome Sciences gewinnen an der NASDAQ vorbörslich 5,49 Prozent auf 10,18 Dollar.

[boersen_freak]

So, heut stell ich mal ein paar gute News ein. WIe schätzt Ihr die weitere Entwicklung von HGS ein ???

Human Genome Sciences receives milestone payment from GSK
After filing an investigational new drug application to begin clinical trials of GSK716155 for the treatment of diabetes, GlaxoSmithKline has made a $5 million payment to the drug`s creator, Human Genome Sciences.

11 Jan 2006, 17:02 GMT - The payment was made pursuant to an agreement between the companies reached in October 2004, under which GSK acquired exclusive worldwide rights to develop and commercialize GSK716155 for all human therapeutic and prophylactic applications.

Human Genome Sciences received an upfront fee and is entitled to significant clinical development and commercial milestone payments that could amount to as much as $183 million, as well as additional milestones for other indications developed.

"We are pleased that GSK has chosen to advance GSK716155 to clinical development. It is our hope that this drug may ultimately offer a new option in the treatment of diabetes," said H Thomas Watkins, president and CEO of Human Genome Sciences.

[gontard]

$17 is 3-6 months target, we have less than 1 month, please give more time to HGSI.

Banc America reiterates HGSI target $17

Last month Banc of America Securities upgraded HGSI on rate "BUY" and with target price $17. Today Banc of America Securities reiterate its rate "BUY" and target for HGSI.

You will see this report in 1 to 2 days.

[gontard]

On May 5, 2005, Vertex was trading at around 10 dollars a share. That week, the company announced preliminary results of their experimental drug VX-950 for Hep C. The drug could be a blockbuster for the company. Since that announcement, Vertex has more than tripled in value to 36 dollars a share.
HGS`s drug for Hepatitis C, also can be a blockbuster. The two drugs will not compete against each other, but rather will be complimentary. Yet, when HGS announces positive trials for their drug, the market gives the shares no boost in value. I think at some point this will change. Here is an excerpt about the two drugs from the analyst at Wachovia:

Maintain Outperform ahead of Albuferon Phase IIb data: We would be buyers on
weakness in HGSI shares following today`s larger than expected losses and strong
data presented by Vertex on VX-950 earlier this week. We believe that HCV
protease inhibitors like VX-950 will prove complementary to rather than serve as
a substitute for interferon-based therapies such as HGSI`s Albuferon, and
continue to anticipate a large market opportunity for Albuferon supported by
what we believe will be positive Phase IIb data expected within the next few
weeks

[africanus]

bin mal gespannt wieviel noch bei human genome auf den zug aufspringen wollen wenn dieser schon längst fast im ziel ist.

warte nur noch auf die richtige nachricht. z.B Phase III oder sogar doch ne übernahme um meine stücke und calls rauszuwerfen.
wenn die news draussen sind kommen die lemminge plötzlich aus ihren löchern.

gut für uns

mfg
africanus

[wallstreetcrash]

[posting]20.461.840 von africanus am 02.03.06 12:35:45[/posting]Warum sollte Deiner meinung nach der Zug schon abgefahren sein..

Ich denke, der Zug beginnt jetzt allmählich erst zu rollen

[africanus]

noch nicht ganz

wollte damit nur zum ausdruck bringen, dass die "echten" news noch nicht draußen sind.

der clevere investor ist schon seit 9,0 dollar dabei
die lemminge kommen wenn die ersten großen news kommen, dann wirds für uns schon langsam wieder zeit auszusteigen

mfg
africanus

[aliekber]

ja langsam dieses Aktien aussteigen oder?

Gruss

[aliekber]

[posting]20.700.853 von aliekber am 15.03.06 16:05:29[/posting]Aber Human Genome steigt und steigt!Warom? wer kann etwas sagen warom steigt Human Genome?Bitte ein Antwort.


Grusss
Danke

[wallstreetcrash]

[posting]20.701.979 von aliekber am 15.03.06 16:32:34[/posting]
weil meiner Meinung nach der Markt gestern zu heftig übertrieben hat und heute nun wieder korrigiert...

[aliekber]

HUMAN GENOME
Ich denke dieses Aktie unterbewertet,ich habe DM seite über 70 DM gekauft aktie fällt boden,viele kleine Aktien damals waren 5,6 Dollar Heute Gleiche Aktien manche sind 70,80 Euro.Jetz Langsam Human genome geht richtung oben.Citibank hat vor 1 Monat als kaufen oben stuft.Ab heute Aktie soll oben gehen.Wenn mann dieses seite manche user liest technisch sollte über 25 Euro sein.Ich glaube Dienstag ist ein Gutes nachrichten haben wir gelessen aber viele haben falsch beurteilt Aktie geht nach unten,Erst Donnertag Nact alle haben verstanden,Aktie war wieder kauf gewesen nach oben gegangen.Heute soll über 10 Euro nacmittag springen,kann noch höche auch sein.Aber heute früh warom wieder so tief ich verstehe nicht.Wenn man Dollar- Euro rechnet trotzdem sollte nähe 10 Euro sein.wer kann wie ich so lang warten weiss ich nicht.Ich werde warten bis Human wieder 70-80 euro wird,dann ich kann verkaufen.Also wer wusste damals solche Aktien für klonen,klorea und enliche dinge machen können.Ohne Ärzte trotz medizin niemand was kann machen.
Gruss an Alle

[aliekber]

Heute 17.03.2006 www.finanz.net und wallstreet-online.de schreibt Das researchteam piper Jaffray stuft die Aktien HUMAN GENOME Outperform.Warom?grund ist offen botte3 lesen sie obere intzernet seite.


Gruss an alle

[gontard]

ales kjar diutschland

[aliekber]

Antwort auf Beitrag Nr.: 20.913.526 von gontard am 22.03.06 19:38:41

[aliekber]

Antwort auf Beitrag Nr.: 20.913.526 von gontard am 22.03.06 19:38:41

Gontardihitotitleriosios

So ein schöne name wer hat gehört,mir gefällt sehr gut!

Mann liesst ganse Geschichte.Mann sicht Deutsche Reich,Romenische reich,Osmanische raich.Und ich habe HUMAN GENOME fergessen,Kurs geht nach unten aber egal für dieses name wenn HUMAN Pleite geht auch keine problem.

Gruss Humanios

[gontard]

uman Genome Sciences (HGSI :

HGSI10.34, +0.22, +2.2% ) climbed 3% to $10.38. Analysts at Thomas Weisel initiated coverage of the biotech group with the rating of peer perform, adding that it saw the company's "fair value" at $10 to $12 a share. End of Story

[bernie55]

Human Genome Sciences "buy"

Rating-Update: Westerburg, 23. Juni 2006 (aktiencheck.de AG)

Die Analysten von Deutsche Securities stufen die Aktie von Human Genome Sciences (/ ) in einer Ersteinschätzung mit "buy" ein. Das Kursziel werde bei 17 USD gesehen.

Quelle: Deutsche Securities

[HSM]

Servus allerseits


Aus "Der Aktionär" mehr aus der aktuellen Ausgabe siehe Thread: Der Aktionär * Empfehlungen * Ausgabe 35/2006


Top-Tipp spekulativ; Human Genome Sciences, risikobereite Anleger legen sich einige Aktien als Depot. Kursziel 15 Euro.

[Talim]

geht bald richtig ab.
Kursziel von verschiedenen Banken bei 12-15 €
ich stoß dann bei 11 € ab

[Talim]

Interessiert sich überhaupt irgendjemand für dieses Papier?
hat ja in den letzten Wochen bereits ordentlich zugelegt

[bernie55]

Antwort auf Beitrag Nr.: 24.256.488 von Talim am 28.09.06 12:10:30

YEPP...immer noch dabei, aber zur Zeit aktiver im ELAN Thread, deshalb diese News etwas verspätet...


ROCKVILLE

Wednesday September 27, 4:10 pm ET



Human Genome Sciences, Inc. (Nasdaq: HGSI - News) today announced that its presentations at its Analyst & Investor meeting will be webcast and may be accessed at http://www.hgsi.com." target="_blank" rel="nofollow ugc noopener">http://www.hgsi.com.


Human Genome Sciences' senior management will provide an overview of the Company on Wednesday, October 4, 2006, beginning at 12 Noon Eastern Time.


Investors interested in listening to the live webcast should log on before the start time in order to download any software required. The archive of the conference call will remain available for several days after the live event.

The mission of Human Genome Sciences is to discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with planned facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. Government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses.

Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

[bernie55]

Human Genome Sciences Reports Positive Results of Phase 1 Clinical Trial of CCR5 mAb in Patients Infected with HIV-1


Friday September 29, 5:00 pm ET
- Phase 1 Study Demonstrates Proof of Concept for the HGS CCR5 mAb Program -
- HGS004 Exhibits Significant Antiviral Activity at Doses of 8 mg/kg or Higher -
- In Vitro Results Predict Greater Antiviral Activity for Alternate CCR5 mAb Candidate, HGS101 -


ROCKVILLE, Md., Sept. 29 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI - News) today announced that the results of a Phase 1 clinical trial of HGS004 (CCR5 mAb) demonstrate that it was well tolerated and exhibited antiviral activity in patients who are infected with HIV-1, the retrovirus that causes acquired immunodeficiency syndrome (AIDS). The results were reported in San Francisco in an oral presentation at the American Society for Microbiology's 46th Annual Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
ADVERTISEMENT


"The availability of the newer classes of antiretroviral agents has produced considerably improved outcomes in the treatment of AIDS and HIV-1 infection, but there is a significant need for novel classes of safe and effective agents that have additive or synergistic activity and a low risk of cross-resistance," said Jacob P. Lalezari, M.D., Director, Quest Clinical Research, Assistant Clinical Professor of Medicine, UCSF/Mount Zion Hospital, San Francisco, and lead investigator for the Phase 1 trial of HGS004. "The results of the Phase 1 study of HGS004, along with preclinical data, warrant additional study of HGS004 and other therapeutic candidates in the HGS CCR5 antibody program."

"The Phase 1 results presented at ICAAC demonstrate proof of concept for the HGS CCR5 antibody program," said William W. Freimuth, M.D., Ph.D., Vice President, Clinical Research, Immunology, Rheumatology and Infectious Disease, HGS. "The study demonstrates that HGS004 was well tolerated and exhibited significant dose-related antiviral activity that correlates well with pharmacokinetic data and with the sensitivity of specific HIV-1 viral strains. We note that data from in vitro studies suggest that HGS101, an alternate CCR5 mAb candidate, is likely to have approximately 5.5-fold greater potency and a broader range of activity against HIV-1 viral strains than HGS004. The other attributes of HGS101 are similar to those of HGS004, including favorable pharmacokinetics, strong in vitro evidence of anti-viral activity that is additive or synergistic in combination with other therapeutic agents, and a low likelihood of the development of resistance. In the coming months, we will determine the best path forward for the HGS CCR5 mAb program."

About the CCR5 mAb Phase 1 Trial

The Phase 1 trial of HGS004 (CCR5 mAb) was a randomized, placebo- controlled, dose-escalation, multi-center study in patients who were infected with HIV-1 and not receiving concurrent antiretroviral therapy. The primary objective was to evaluate the safety and tolerability of escalating doses of a single intravenous (IV) infusion of HGS004. The secondary objectives were to determine the pharmacokinetics of HGS004, and to assess its effect on plasma HIV-1 viral load and on CD4+ and CD8+ T-cell counts over time. Patients were followed for 56 days after study agent administration.

The results of the Phase 1 trial were reported today at ICAAC in an oral presentation entitled "A Phase 1, Randomized, Dose-Escalation, Placebo- Controlled Study of a Fully Human Monoclonal Antibody Against CCR5 (HGS004) in Patients with CCR5 Tropic HIV-1 Infection." A total of 54 patients were randomized and enrolled into 6 dose cohorts at a ratio of 4:1 (active: placebo). In each cohort, patients received a single IV infusion of HGS004 or matching placebo (0.4 mg/kg, 2 mg/kg, 8 mg/kg, 20 mg/kg, and 40 mg/kg). The results demonstrate that HGS004 was well tolerated following administration of a single IV dose up to 40 mg/kg. A significantly higher antiviral response was observed in patients receiving HGS004 at doses of 8 mg/kg or greater. At these doses, a dose response was observed in viral load reduction at Day 14, vs. placebo or the lower-dose cohorts (p<0.0001). A viral load reduction of > or = 1.0 log was observed at Day 14 in 57.9% (11/19) of the patients receiving HGS004 at doses of 8-20 mcg, and 50% (5/10) of the patients receiving HGS004 at a dose of 40 mg/kg. At Day 28, a trend to dose response was observed for doses > or = 8mg/g, vs. placebo or the 0.4 and 2 mg/kg cohorts (p=0.0007). Increases in CD4+ and CD8+ T-cell counts from baseline were observed in the majority of subjects receiving HGS004. The pharmacokinetics of HGS004 were non-linear across the range of doses studied, with a dose-proportional C-max increase and a greater than dose-proportional AUC increase. HGS004 exhibited an elimination half life of 5-8 days. At doses of 8 mg/kg or greater, CCR5 receptor occupancy (RO) of greater than 80% was observed from Day 14 through Day 28. Significant RO was maintained through Day 56 in the three higher dose cohorts. HGS004 was well tolerated even at the highest dose of 40 mg/kg. Two treatment-related moderately severe adverse events of transient infusion- related urticarial rash were observed in the 2 mg/kg treatment cohort. Subsequent patients were pretreated with Benadryl, and no additional instances of urticarial rash were reported. There were no clinically significant laboratory abnormalities.

About HGS004 (CCR5 mAb)

HGS004 is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (HIV-1). HGS004 was generated by HGS using the Abgenix XenoMouse® technology. The HGS CCR5 mAb program also includes HGS101, a fully human antibody which in vitro data suggest is likely to be approximately 5.5 times more potent than HGS004, with activity against a broader range of HIV-1 viral strains.

About Human Genome Sciences

The mission of Human Genome Sciences is to discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs.

The HGS clinical development pipeline includes drugs to treat hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. The Company's primary focus is rapid progress toward the commercialization of its two lead compounds, Albuferon(TM) for hepatitis C, and LymphoStat-B(TM) for lupus. Both compounds are expected to advance to Phase 3 clinical trials in 2006.

In June 2006, HGS announced that the U.S. Government exercised its option under an existing contract to purchase 20,000 doses of ABthrax(TM) for the treatment of anthrax disease. Other HGS compounds in clinical development include three TRAIL receptor antibodies for the treatment of hematopoietic and solid malignancies, in addition to an antibody to the CCR5 receptor for the treatment of HIV/AIDS.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. For more information on CCR5 mAb, visit http://www.hgsi.com/products/CCR5.html. Health professionals or patients interested in inquiring about clinical trials involving HGS products in development are encouraged to inquire via the Contact Us section of the company's web site, http://www.hgsi.com/products/request.html, or by calling us at [phone], extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

http://biz.yahoo.com/prnews/060929/dcf047.html?.v=35

[WhiteRabbit]

[Talim]

neues KZ vom Aktionär auf 15 € gesetzt... an und für sich guter Newsflow, doch leider heute schon ordentlich nachgegeben.
aber das wird schon wieder
nach wie vor halten !

[bernie55]

Analysten-Bewertung - 12.10.06


Rating-Update: New York (aktiencheck.de AG)
Die Analysten von Lazard Capital Markets stufen die Aktie von HGSI in einer Ersteinschätzung mit "sell" ein.
Das Kursziel werde bei 8 USD gesehen. (12.10.2006/ac/a/u


Rating-Update: San Francisco (aktiencheck.de AG)
Die Analysten von Thomas Weisel stufen die Aktie von HGSI in ihrer Erstempfehlung mit "outperform" ein.
Der Fair Value werde bei 18 bis 19 USD gesehen. (12.10.2006/ac/a/u)

[bernie55]

Human Genome says FDA OKs late stage trials for LymphoStat-B


Thu Oct 26, 2006 6:27am ET


Oct 26 (Reuters) - Human Genome Sciences Inc. (HGSI.O: Quote, Profile, Research) on Thursday said it received a special protocol assessment from regulatory authorities for late stage clinical trials of its monoclonal antibody drug, LymphoStat-B, in patients suffering from systemic lupus erythematosus.

Systemic lupus erythematosus is a chronic, inflammatory disease, affecting the skin, joints, kidneys and marked by skin rashes and joint pain.

The biotech company said it expects to initiate the late stage trials before the end of 2006 !!!!! and said the clinical study, which was approved by the U.S. Food and Drug Administration, was a critically important step for the company's evolution as a commercial organization.

(Reporting by Rakesh Sharma in Bangalore)


http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn…

[kevin.lomax]

Human Genome says Hepatitis C treatment promising

Wednesday, November 01, 2006 3:57:18 AM ET
newratings.com

NEW YORK, November 1 (newratings.com) – Human Genome Sciences Inc (HGSI.NAS) Tuesday announced that its chronic Hepatitis C treatment, Albuferon, has shown positive results in an ongoing clinical trial.

Human Genome Sciences said that the results refer to the first 24 weeks of a 48-week study involving patients who are being tested for Albuferon, along with Roche’s Ribavirin. The first part of the study revealed that the treatment reduced the overall rate of the virus in 21% of the patients. The drug is safe and effective, the results revealed. Human Genome Sciences is developing the drug in collaboration with Novartis. The company said that it expects the Phase III clinical trials to begin by the end of the year.

[aliekber]

Human Genome Sciences "buy"

31.01.2007
Stifel Nicolaus

Rating-Update:

Baltimore (aktiencheck.de AG) - Die Analysten von Stifel Nicolaus stufen die Aktie von Human Genome Sciences (ISIN US4449031081 / WKN 873205) in ihrer Ersteinschätzung mit "buy" ein. Das Kursziel sehe man bei 18 USD. (31.01.2007/ac/a/u)

[aliekber]

08.01.2007 14:23
Human Genome hält an Zielen fest
Das Biotechnologieunternehmen Human Genome Sciences Inc. (Nachrichten/Aktienkurs) hat seine Prognosen für 2006 bestätigt und rechnet für jene Periode weiterhin mit einer Barmittel-Verbrennung von weniger als 125 Millionen Dollar. Für das vierte Quartal wird eine nicht barmittelwirksame Sonderbelastung in Aussicht gestellt.

Für 2007 geht das Unternehmen von einem Barmittelverbrauch von 145-165 Millionen Dollar aus. Die Erlöse sollen gegenüber 2006 um rund 50% zulegen. Die Ausgaben für Forschung, Entwicklung und allgemeinen Unternehmensangelegenheiten sollen sich im Vergleich zum Vorjahr weitgehend fla08.01.2007 14:23
Human Genome hält an Zielen fest
Das Biotechnologieunternehmen Human Genome Sciences Inc. (Nachrichten/Aktienkurs) hat seine Prognosen für 2006 bestätigt und rechnet für jene Periode weiterhin mit einer Barmittel-Verbrennung von weniger als 125 Millionen Dollar. Für das vierte Quartal wird eine nicht barmittelwirksame Sonderbelastung in Aussicht gestellt.

Für 2007 geht das Unternehmen von einem Barmittelverbrauch von 145-165 Millionen Dollar aus. Die Erlöse sollen gegenüber 2006 um rund 50% zulegen. Die Ausgaben für Forschung, Entwicklung und allgemeinen Unternehmensangelegenheiten sollen sich im Vergleich zum Vorjahr weitgehend flach entwickeln.

Die Summe aus dem Barmittelverbrauch und den Investitionen wird bis Ende 2007 in einer Spanne von 560-580 Millionen Dollar ewartet.


ch entwickeln.

Die Summe aus dem Barmittelverbrauch und den Investitionen wird bis Ende 2007 in einer Spanne von 560-580 Millionen Dollar ewartet.

[aliekber]

Update Human Genome Sciences Inc.: Buy
04.01.2007 16:23:46
Die Analysten von AG Edwards bewerten in ihrer Analyse vom Donnerstag, 4. Januar 2007 die Aktie von Human Genome Sciences Inc. neu mit dem Rating "Buy". Das Kursziel für die Aktie liegt momentan bei 17 $.


31.01.07 Update Human Genome Sciences Inc.: Buy
31.01.07 Human Genome Sciences buy
04.01.07 Update Human Genome Sciences Inc.: Buy
21.11.06 Update Human Genome Sciences Inc.: Positive
09.11.06 Human Genome Sciences Downgrade

[bernie55]

Rating-Update: Baltimore (aktiencheck.de AG) -

Die Analysten von Stifel Nicolaus stufen die Aktie von Human Genome Sciences (<-->/ WKN 873205) in ihrer Ersteinschätzung mit "buy" ein. Das Kursziel sehe man bei 18 USD.

(31.01.2007/ac/a/u)

[Fruehrentner]

Human Genome Sciences starts second Phase III study of Albuferon for hepatitis C

Human Genome Sciences has started a second Phase III trial
of its lead developmental product, Albuferon (albumininterferon
alfa-2b), for the treatment of chronic hepatitis C.
The US company says that if Phase III results are positive it
expects to make global filings in 2009.
HGS believes that its product could become the “treatment
of choice” for chronic hepatitis C. The lead investigator of the
latest trial, Dr David Nelson of the University of Florida, said
that Albuferon needed half as many injections and had the
potential for less impairment of health-related quality of life
than the standard treatment, Roche’s Pegasys (peginterferon
alfa-2a), with at least comparable efficacy.
The Phase III ACHIEVE 2/3 non-inferiority study will compare
Albuferon plus ribavirin with Pegasys plus ribavirin in
treatment-naive patients with hepatitis C genotypes 2 and 3.
Another pivotal trial, ACHIEVE 1, started in December
comparing the same treatments in those with genotype 1
disease. HGS plans to complete enrolment in both studies by
the end of the year.
In both studies, patients will receive Albuferon dosed at
900μg or 1,200μg every two weeks, or Pegasys 180μg once a
week. The primary endpoint of each trial is sustained
virological response (defined as undetectable viral load -
hepatitis C virus RNA <10IU/ml) at week 72 in ACHIEVE 1 and
week 48 in ACHIEVE 2/3.
...Phase IIb
Meanwhile, HGS reported promising preliminary results in a
Phase IIb trial of Albuferon in patients with genotype 1
chronic hepatitis C.
The company plans to present full details of the interim data
on April 14th at the 42nd meeting of the European
Association for the Study of the Liver, and expects results
from the completed trial to be available in the middle of
the year.
The 458-patient non-inferiority study is examining Albuferon
doses of 900μg every two weeks, 1,200μg every two weeks,
and 1,200μg every four weeks. The primary endpoint is
sustained virological response (SVR) at 24 weeks. The results
at week 12, which have just been released, are thought to be
highly predictive of SVR.
The preliminary data showed a higher rate of SVR at 12
weeks (SVR12) in patients on a 900μg dose of Albuferon
compared with those receiving Pegasys. Health-related
quality of life scores (measured by SF-36) were also higher in
the Albuferon group.
Among treatment-adherent patients (those with over 80%
adherence), 73.8% of those receiving Albuferon 900μg and
72% on Albuferon 1,200μg reached SVR12, versus 63% in
the Pegasys group. Lower relapse rates were also seen in
treatment-adherent patients in all Albuferon groups than
those on Pegasys.
In patients on the highest dose every four weeks, SVR12
rates were comparable with those on Pegasys. HGS said that
this lower than expected response could be due to a higher
discontinuation rate in the 1,200μg group, and that it planned
a more effective dose-modification strategy in the ongoing
Phase III trials.
Nevertheless, the company believes that the results support
further evaluation of monthly administration of Albuferon,
and said that another Phase IIb study evaluating higher doses
of the product given every four weeks would begin this year.
HGS has not disclosed the doses to be studied yet, but said it
was evaluating 1,500μg and 1,800μg doses in a separate
Phase II trial.
...licensing deal
Last June Novartis licensed the product, and the two
companies will co-promote it in the US, with Novartis having
exclusive marketing and promotion rights in the rest of the
world (Scrip No 3164, p 10).
Albuferon is a long-acting interferon created by the genetic
fusion of human albumin and interferon alfa. HGS says that
human albumin decreases clearance and prolongs the halflife
of the product. Interferon alfa is already used to treat
hepatitis B and C and various cancers.

[bernie55]

Human Genome reports positive Albuferon study

SAN FRANCISCO (MarketWatch) --

5:56am 04/16/2007


The Albuferon group also had more favorable health-related quality-of-life scores than those who were given Pegasys, Human Genome said in a statement.

"The 900-mcg Albuferon dose has the potential to offer patients an attractive therapeutic option, given the favorable antiviral response data, more favorable quality of life effects, and half as many injections," said Human Genome's executive vice president of research and development, David Stump, in a statement.
Albuferon was also shown to be at least as effective as Pegasys regardless of the dosage.
"We and our collaborator, Novartis, are currently planning an additional study to identify the optimal dose for Albuferon dosed monthly," Stump said.
The results were presented over the weekend at the annual European Association for the Study of the Liver in Barcelona.

http://www.marketwatch.com/news/story/human-genome-reports-p…


Nähere Infos:
http://biz.yahoo.com/prnews/070414/nesa001b.html?.v=1

[EurorumDreher]

26.06.2007 16:31
Human Genome Sciences Inc.: equal weight (Lehman Brothers)
Rating-Update:

New York (aktiencheck.de AG) - Die Analysten von Lehman Brothers stufen die Aktie von Human Genome Sciences (ISIN US4449031081 (Nachrichten/Aktienkurs)/ WKN 889323) von "overweight" auf "equal weight" zurück. Das Kursziel werde von 15 auf 10 USD gesenkt. (26.06.2007/ac/a/u)
Analyse-Datum: 26.06.2007


Kein Wunder das bei solchen Meldungen der Kurs solche Sätze nach unten macht.



http://www.worldofinvestment.com/wkn/504350/